 ISELIN, N.J., Sept. 07, 2022 GLOBE NEWSWIRE -- Outlook Therapeutics, Inc. Nasdaq: OTLK, a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022. 